Company Will Develop Instrumentation and Cloud-based Analytical Tools to Accelerate Scientific Discovery
Seattle, WA - September 19, 2016 - FenoLogica Biosciences Inc., a Seattle-WA-based life sciences company, announces completion of a licensing and collaboration agreement with the Pacific Northwest Research Institute (PNRI). FenoLogica also announces closing of its seed investment round that took place on June 13, 2016.
FenoLogica’s technology combines novel quantitative biology measurement techniques with cloud-based analytical tools that are applicable to a wide range of high-content microbiology environments. The resulting platform will allow scientists and researchers to rapidly gain insights into the causes of disease, and expedite the discovery of new treatment options for patients.
The company is led by Seattle-based technology and life sciences executive, Sean MacLeod. MacLeod has 25 years of experience as a business executive, entrepreneur and engineer with a focus on life science applications and medical device technology. He has mentored and advised numerous organizations on strategy, market diligence, intellectual property commercialization and product development. In his previous role as President of Stratos Product Development, MacLeod was instrumental in the development of many successful technologies for companies including Abbott, BD Biosciences, AcelRX Pharmaceuticals, Novo Nordisk, Proteus Digital Health, OpGen and Philips Healthcare.
“A successful product requires the right science and technology, the right market opportunity and the right team,” Sean MacLeod, CEO and Founder, FenoLogica, said. “With several promising market opportunities identified, we are in a great position to introduce new tools that address emerging discovery and clinical needs. I look forward to building a team and leading the efforts to commercialize PNRI’s proven technology.”
During initial product development, MacLeod and his team will work closely with the scientists at PNRI to ensure successful implementation and commercialization of its quantitative biology platform. FenoLogica anticipates releasing its first product in early 2018.
“Leveraging our most promising scientific results to accelerate medical research and improve people’s health is a core value at PNRI,” John Wecker, CEO, PNRI, said. “It’s exciting to see the technologies that have been developed by the Institute’s scientists find a path to meaningful commercial applications. We’re thrilled to see one of these emerging technologies in the capable hands of Sean MacLeod."
About FenoLogica Biosciences
Looking Beyond the Cell - Quantitative Biology in the Cloud
FenoLogica helps scientists gain insights into complex cellular interactions, creating a deeper understanding of disease to improve patient outcomes. Our combined instrumentation and cloud-based quantitative biology tools expedite the understanding of disease susceptibility and causation, leading to optimized therapeutic solutions. The FenoLogica platform provides advanced analytical capabilities that will enable ambitious next generation ex vivo diagnostic applications.
For more information, visit www.fenologica.com.
About Pacific Northwest Research Institute
PNRI is a non-profit, biomedical research institute in Seattle, WA, USA, founded in 1956 by Dr. William Hutchinson with the vision to provide a welcoming place for scientists to independently pursue their research interests. Today, PNRI continues to seek novel ways to prevent, treat and cure human diseases using the latest and most promising technologies. The Institute's team of more than 100 physicians, scientists and technical staff work independently and collaboratively to realize scientific discoveries, generate insight into disease processes, and improve the health of people around the world.
For more information, visit www.pnri.org.